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Colon targeted drug delivery is an active
area of research for diseases affecting the
colon, as it shows promise in improving
the efficacy of therapeutics and reduc-
ing systemic toxicity. Improved oral
drug delivery design has unequivocally
improved the bioavailability of drugs to
the colon. The oral route of adminis-
tration is the most common method of
drug delivery. It is the preferred route
of administration because of increased
patient convenience and reduced invasive-
ness. Rectal formulations may seem ideal
for colon targeted drug delivery; how-
ever in addition to the issues surrounding
patient administration, the efficacy of
these formulations is limited to condi-
tions affecting the distal colon and rectum.
They are not effective for the treatment of
more widespread inflammation of the
colon, which occurs in conditions such as
Inflammatory Bowel Disease (IBD).
Oral formulations can be designed to
achieve either a local or systemic delivery
of therapeutics. Local treatment requires
that the drug will be delivered to the site
of action within the gastrointestinal (GI)
tract to have a localized effect, but will
not be absorbed or only poorly absorbed.
Systemic delivery for orally adminis-
tered drugs requires systemic absorption
occurring within the intestines prior to
distribution of drug around the body.
For conditions involving localized inflam-
mation to the tissues of the colon, the
ideal formulation would be one that (i) is
administered orally, (ii) is able to reach the
colon, (iii) delivers high concentrations of
drug at the site of inflammation, and (iv)
is not systemically absorbed.
Current formulations have limited
effect on specificity of targeting to diseased
colon tissue vs. healthy colon tissue. In
addition, despite coverage to the surface of
the colon (including diseased tissue), there
is no guarantee that the drug is effectively
taken up into the tissue and cells at the
site of inflammation. Therefore, the use
of nanotechnology in formulation design
has been investigated as a way to further
improve the efficacy of therapeutics by
allowing specific targeting and uptake into
inflamed tissue within the colon (Jani
et al., 1989, 1990).
Nanoformulations have been devel-
oped for the targeted treatment of a num-
ber of pathological conditions, including
IBD, cancers, and infections (Vingerhoeds
et al., 1994; Singh, 1999; Maruyama,
2002). For the purpose of GI tract target-
ing, liposomes can be manipulated by the
inclusion of polymer coatings on the lipo-
somal surface. These coatings allow oral
liposomal formulations to resist degrada-
tion in the hostile environment of the GI
tract, which include bile salts and enzymes
(e.g., pancreatic lipases) that would nor-
mally dissolve the lipid bilayer (Iwanaga
et al., 1999; Takeuchi et al., 2003; Karn
et al., 2011). This article will briefly discuss
strategies which have been investigated for
targeting drug-encapsulated liposomes to
the colon.
NATURAL POLYMERS—CHITOSAN
AND PECTIN
Chitosan and pectin are natural polymers
that are considered non-toxic, biodegrad-
able, and mucoadhesive. Adhesion to the
mucosa is an advantage for GI tract target-
ing as it promotes the direct contact of the
liposomes to the mucosal surface for cel-
lular uptake and drug release, and reduces
the clearance of liposomes when intestinal
motility is increased, which occurs in con-
ditions such as IBD (Thirawong et al.,
2008a,b; Mady et al., 2009; Nguyen et al.,
2011; Han et al., 2012). The mucoadhesive
property of natural polymers is thought
to be due to the electrostatic interaction
between the cationic polymer, and the
anionic sulfonic and sialic acid residues
within the mucus matrix (Han et al.,
2012).
Chitosan-coated liposome formula-
tions have shown increased stability in
simulated gastric and intestinal fluids
(Han et al., 2012), as well as improved
drug uptake in colon tissue ex vivo in com-
parison to uncoated liposomes (Takeuchi
et al., 2003; Gradauer et al., 2012, 2013;
Han et al., 2012; Manconi et al., 2013).
Thirawong et al. (2008a,b) evaluated
the mucoadhesion and uptake of orally-
administered pectin-coated liposomes
in vivo and was able to demonstrate
increase residence of these nanoparti-
cles in the GIT mucosa, with very little
colloidal aggregation (Thirawong et al.,
2008b). However, the majority of the for-
mulation was found to accumulate in the
small intestine, with little uptake in the
colon (Thirawong et al., 2008b). The use
of colon-specific enteric coating such as
Eudragit® may be used to overcome this
issue.
SYNTHETIC
POLYMERS—EUDRAGITS®
Eudragit® is a synthetic copolymer coat-
ing that combines both the mucoadhe-
sive and pH-dependent release strategies,
to enhance colon targeted drug deliv-
ery via the oral route of administration.
Eudragits® are methacrylic co-polymers
with varying side group compositions that
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alter the pH at which they are solu-
ble (Barea et al., 2012). They are widely
used in oral pharmaceutics as enteric
coatings of tablets and capsules (Khan
et al., 1999, 2000; Barea et al., 2012).
Eudragit®-coated liposomal and micro-
sphere formulations have demonstrated
favorable pH-dependent release character-
istics in vitro (Xing et al., 2003; Haznedar
and Dortunc, 2004; Barea et al., 2010).
For example, Barea et al. (2010) reported
a significant reduction in drug release
from Eudragit®-coated liposomes at pH
1.4 (stomach) and pH 6.3 (small intes-
tine), and significant drug release at pH
7.8 (ileocaecal region) (Barea et al., 2010).
The study also reported degradation of
the Eudragit®-coating by bile salts in vitro,
which would adversely affect its efficacy
in vivo by causing premature degrada-
tion of the liposomes and release of the
drug in the duodenum. Karn et al. (2011)
demonstrated using freshly extracted pig
intestine tissue that liposomes coated with
Eudragit® have superior mucoadhesion
characteristics, in comparison to other
common polymers such as chitosan and
carbopol (Karn et al., 2011). These stud-
ies show that the use of Eudragit® as a
coating over nanoparticles would be able
to target the colon and provide effective
drug release, however further formulation
design is required to address the vulnera-
bility of this coating to bile salts.
ACTIVE
TARGETING—IMMUNOLIPOSOMES
The use of polymers to coat liposomal
formulations has enhanced drug deliv-
ery to the colon following oral admin-
istration, via pH-dependent release and
mucoadhesive characteristics. However,
these formulations have limited effect on
specificity of targeting to diseased colon
tissue vs. healthy colon tissue. Active
targeting approaches with the coupling
of ligands to the surface of nanoparti-
cles (e.g., liposomes) would allow more
specific targeting to regions within the
colon, by exploiting disease-induced cel-
lular changes in cell-surface receptors and
proteins. The coupling of antibodies, par-
ticularly monoclonals, to create immuno-
liposomes represents one of the more
versatile ligands that can be affixed to
liposome surfaces. In particular, it has
been demonstrated that specific delivery of
drugs to the target cells is far more effi-
cient with immunoliposomes than with
liposomes lacking a target antibody lig-
and (Vingerhoeds et al., 1994; Willis and
Forssen, 1998; Bendas, 2001; Maruyama,
2002). The majority of the work in the
field of immunoliposome-based formula-
tions has been studied using the parenteral
route of administration (e.g., intravenous,
subcutaneous, intraperitoneal injection)
(Vingerhoeds et al., 1994; Willis and
Forssen, 1998; Bendas, 2001; Maruyama,
2002).
Oral administration of immunolipo-
somes has its challenges, as the antibodies
are prone to degradation by the stomach
acid as well as by GI tract enzymes. In
addition, the liposomal bilayer is digested
by the bile salts and enzymes if not pro-
tected by an additional coating. Much of
the research on targeted drug delivery
to the GI tract has centered on deliv-
ery of chemotherapeutics to intestinal
cancers, via liposomes conjugated to anti-
bodies raised against receptors which
are over-expressed in both tumors and
tumor-associated tissues during carcino-
genesis (Koning et al., 1999, 2002; Mizoue
et al., 2002; Guin et al., 2011; Wicki et al.,
2012). These studies are usually limited to
in vitro or ex vivo cell association experi-
ments, and have shown positive results in
specificity of cell targeting and uptake.
Immunoliposomes also have inherent
mucopenetrative properties, which fur-
ther support its use in targeting inflamed
intestinal mucosal tissue (Saltzman et al.,
1994; Shen et al., 2006). For example,
Harel et al. (2011) demonstrated a 4-fold
increase in transferrin receptor (TfR)-
targeted immunoliposome uptake in
freshly excised intestinal mucosal tis-
sue from a rodent induced-colitis model
of IBD in comparison to uninflamed
excised rat tissue (Harel et al., 2011).
These results demonstrate that the use
of immunoliposomes is promising for tar-
geting specifically inflamed regions within
the colon, which occurs in conditions
such as IBD.
Intercellular adhesion molecule-1
(ICAM-1) has been shown to be upregu-
lated in inflammatory regions of the colon,
which occurs in conditions causing colitis
and in IBD (Binion et al., 1997, 1998; Sans
et al., 1999; Danese et al., 2005). ICAM-
1 is expressed more prominently on the
surface of inflamed intestinal mucosal tis-
sues and microvasculature (Salmi et al.,
1994; Bernstein et al., 1996). In Crohn’s
Disease, ICAM-1 is also expressed in
deeper tissues such as the submucosal
and muscle layers, which promote trans-
mural invasion of leukocytes (Hogaboam
et al., 1996). ICAM-1 targeted nanopar-
ticles for oral drug delivery has recently
been investigated by Mane and Muro
(2012). This study evaluated the biodistri-
bution and uptake of empty anti-ICAM-1
antibody-coated nanocarriers composed
of the polymer, polystyrene, in the GI
tract following gastric gavage in healthy
mice. As expected, approximately 60% of
the antibody dose administered (1.1mg
antibody per kg) was degraded, which was
attributed mainly to GI tract enzymes. The
nanocarriers were deposited mainly in the
stomach and duodenum, which suggest
more upper GIT targeting. Using trans-
mission electron microscopy and energy
dispersive X-ray spectroscopy, they were
also able to demonstrate internalization of
the radiolabelled nanocarriers within duo-
denal tissue via ICAM-1 (Mane and Muro,
2012). This work shows the importance
of ICAM-1 in the GIT, and the poten-
tial of ICAM-1 targeted nanocarriers in
the delivery of therapeutic agents for the
treatment of pathologies of the GIT.
FUTURE ADVANCES IN ORALLY
ADMINISTERED LIPOSOMAL
FORMULATIONS FOR COLON
TARGETED DRUG DELIVERY
Specific drug delivery to the colon is
highly desirable for local treatment of a
variety of bowel diseases such as ulcer-
ative colitis, Crohn’s disease, infections
and colorectal cancer. Contrary to most
therapeutic regimens utilizing oral admin-
istration, systemic absorption is an unde-
sirable delivery feature for these drugs.
Disease localization dictates the need for
maximal intestinal tissue drug exposure
while systemic delivery should be min-
imized to avoid unwanted side effects.
Delayed or controlled release dosage forms
have proven beneficial to negate upper
intestinal absorption and release the drug
at the sites of disease. The potential to
increase drug residence time in regions of
diseased tissue would serve to further opti-
mize this therapy. The use of nanopartic-
ulate, mucoadhesive, and active targeting
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dosage forms are promising strategies to
target and adhere to diseased bowel tissue,
and could provide sustained exposure of a
therapeutic agent to sites of pathology and
improve its therapeutic effect.
The use of liposomes has been shown to
selectively target inflamed tissue, with the
disruption of the intestinal barrier func-
tion at the site of inflammation allowing
accumulation of particulate delivery car-
riers. Liposomes can also be modified to
enhance binding and cellular uptake to
diseased tissue by the use of cationic lipids
or the attachment of targeting ligands
(e.g., antibodies, peptides). Future stud-
ies will need to assess whether there is a
significant difference in specificity in bind-
ing and accumulation of targeted lipo-
somes vs. charged non-targeted liposomes.
In addition, a combination of measures
will need to be investigated to protect
the liposomes and targeting ligands from
degradation in the GI tract, including from
bile salts, GI enzymes and stomach acid.
For example, the use of polymer coatings
or encapsulating freeze dried liposomes
in capsules coated with pH-dependent
release polymer may be considered (Gupta
et al., 2013). Additional strategies will need
to address potential bile salts degradation
of the liposomal and polymer coatings.
Finally, further in vivo studies are war-
ranted to evaluate the colon targeted oral
formulations in animal models of colonic
inflammation. Formulating an oral deliv-
ery system that can effectively targeted
diseased tissue within the colon has the
potential to be modified to encapsulate
a multitude of drugs, novel compounds,
or imaging agents for the treatment or
management of a number of pathologies
affecting the colon.
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